Israeli pharmaceutical company Kamada expects to receive Food and Drug Administration (FDA) approval for its new lung treatment Glassia in early July.
The product, delivered intravenously, is used to treat Alpha-1 Antitrypsin deficiency (AATD), a shortage or absence of the A-1 Antitrypsin protein that blocks the destructive effects of certain enzymes, which in turn can cause kill tissue and cause chronic lung diseases, such as emphysema.
The genetic disorder has also been linked with liver problems in children.
Company officials believe the FDA will finish their examination of its biological licence application before early July.
Kamada said it had set up a subsidiary called Kamada Inc as part of its preparations to market the drug in the United States.
Copyright Press Association 2010